Concepedia

Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs

Handan He, Phi Tran, Hequn Yin, Harold T. Smith, Dennis J. Flood, Roger Kramp, Ron Filipeck, Volker Fischer, Dan Howard

Drug Metabolism and Disposition · 2008 · 29 citations · 12 references

DOI

Concepts

References

12

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

M. Gutniak, Jens J. Holst, Bo Åhrén et al. · New England Journal of Medicine · 1992 · 875 citations · Full text

, , +17

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Carolyn F. Deacon, Anders H. Johnsen, Jens J. Holst · The Journal of Clinical Endocrinology & Metabolism · 1995 · 757 citations

, , +16

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(<i>S</i>)-pyrrolidine:  A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

Edwin B. Villhauer, J. A. Brinkman, Goli B. Naderi et al. · Journal of Medicinal Chemistry · 2003 · 613 citations · Full text

, , +12

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 519 citations

, , +14

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

Carolyn F. Deacon · The Journal of Clinical Endocrinology & Metabolism · 1995 · 273 citations

, , +13